Highlights Gan & Lee Pharmaceuticals.

Equities

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 13/01/2026			5-day change	1st Jan Change
70.10 ^CNY	+0.31%		+1.49%	+2.98%

01-02	Gan & Lee Pharmaceuticals Removes CFO, Appoints Acting CFO	MT
12-29	Lupin Limited Enters into License, Supply and Distribution Agreement with Gan & Lee Pharmaceuticals for Novel GLP-1 Receptor Agonist, Bofanglutide	CI

Highlights

12-29	Lupin Limited Enters into License, Supply and Distribution Agreement with Gan & Lee Pharmaceuticals for Novel GLP-1 Receptor Agonist, Bofanglutide	CI
12-09	Gan & Lee Pharmaceuticals Gets Clinical Trial Approval For Atopic Dermatitis Drug	MT
11-18	Gan & Lee Pharmaceuticals Europe GmbH Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Recommends the Approval of Insulin Glargine Injection	CI
30/10/25	Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
29/09/25	Gan & Lee Pharmaceuticals Signs National "Technology Transfer and Supply Agreement" in Brazil to Accelerate Local Insulin Manufacturing	CI
07/09/25	Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.	CI
02/09/25	Gan & Lee Pharmaceuticals.'s Equity Buyback announced on September 6, 2024, has expired with 3,540,021 shares, representing 0.6% for CNY 150.07 million	CI
08/08/25	Gan & Lee Pharmaceuticals' lH1 Profit Jumps 103%, Revenue Rises 57%	MT
07/08/25	Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
07/08/25	Gan & Lee Pharmaceuticals' H1 net profit up 102.0% Y/Y	RE
09/07/25	Gan & Lee Pharmaceuticals sees H1 net profit up 100.7-114.1% Y/Y	RE
08/07/25	Gan & Lee Pharmaceuticals' Insulin Aspart Receives Approval in Argentina	CI
21/06/25	Gan & Lee Pharmaceuticals Presents Multiple Results in Novel Diabetes Therapies At the American Diabetes Association's 85Th Scientific Sessions	CI
25/04/25	Gan & Lee Pharmaceuticals' 2024 Profit Jumps 81%, Operating Income Rises 17%; Shares Jump 10%	MT
25/04/25	Gan & Lee Pharmaceuticals' Q1 Profit Surged 225%, Operating Income Jumps 76%; Shares Jump 10%	MT
24/04/25	Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
23/04/25	Gan & Lee Pharmaceuticals Gets Nod to Trial Diabetes Drug	MT
02/04/25	Gan & Lee Pharma's Insulin Glargine Injection Gets Registration Nod in Pakistan	MT
01/04/25	Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.	CI
10/03/25	Gan & Lee Pharmaceuticals Announces First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide Injection for Overweight or Obesity	CI
11/02/25	Gan & Lee Pharmaceuticals Registers Diabetes Treatment Drug	MT
02/01/25	Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.	CI
13/12/24	Gan & Lee Pharmaceuticals Gets US FDA Approval for Clinical Trials of Weight Control Drug	MT
12/11/24	Gan & Lee Pharmaceuticals Announces Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks	CI
11/11/24	Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Gan & Lee Pharmaceuticals.

Equities

603087

CNE100003ZH1

Pharmaceuticals

Highlights

Filters